Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
leflunomide · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| leflunomide | DRUG | - |
| procarbazine hydrochloride | DRUG | - |
| mitoxantrone hydrochloride | DRUG | - |
| prednisone | DRUG | - |
DISEASE CHARACTERISTICS: Histologically proven refractory or recurrent supratentorial glioblastoma multiforme Bidimensionally measurable, enhancing residual disease by T1-weighted gadolinium-enhanced MRI required within 15 days prior to treatment Stable dose of corticosteroids required for at least ...
Leflunomide is being studied for use in oncology, specifically for prostate cancer and brain and central nervous system tumors. It is an investigational small molecule being developed by Pfizer, Inc. (PFE). In clinical trials, it has been evaluated in patients with glioblastoma multiforme, anaplastic astrocytoma, and stage IV prostate cancer.
Leflunomide is a small molecule that inhibits dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis. By blocking this enzyme, it disrupts DNA synthesis and cell proliferation, which is relevant to its anticancer activity. This mechanism is being explored in the treatment of brain tumors and prostate cancer.
Leflunomide is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's efficacy in treating prostate cancer and brain and central nervous system tumors.
Leflunomide is in Phase 3 clinical development for brain and central nervous system tumors, specifically glioblastoma multiforme. It has also completed Phase 2 trials for anaplastic astrocytoma and prostate cancer. The drug is investigational and has not been approved by the FDA for these oncology indications.
Leflunomide has been studied in three completed clinical trials. NCT00003293 was a Phase 3 trial comparing SU-101 with procarbazine in glioblastoma multiforme. NCT00003775 was a Phase 2 trial in anaplastic astrocytoma. NCT00004071 was a Phase 2 trial combining leflunomide with mitoxantrone and prednisone in stage IV prostate cancer.
In the clinical trial NCT00003293, leflunomide is referred to as SU-101. This trial compared SU-101 with procarbazine in patients with glioblastoma multiforme. The drug is also known by the name leflunomide in other trials, such as NCT00003775 and NCT00004071.